2018
|
|
- Moderna’s common stock began trading on the Nasdaq Global Select Market under the ticker symbol “MRNA”
|
---|
|
- Moderna opens its state-of-the-art clinical development site in Norwood, MA
|
|
- Completion of $500m series G equity financing. Total cash raised: $2.5 billion
|
 |
- mRNA-8601 (VEGF) proceeds to Phase 2 clinical development – first Moderna candidate to reach Phase 2
|
2017
|
|
- Moderna announces first therapeutic rare disease development candidate, mRNA-3704, for methylmalonic acidemia
|
---|
 |
- Moderna and Merck initiate first-in-human dosing for mRNA-4157, a personalized cancer vaccine
|
 |
- License and collaboration with AstraZeneca to co-develop/co-commercialize AZD7970, an mRNA therapeutic encoding for relaxin
|
 |
- Moderna’s first human data published in Molecular Therapy from study of mRNA 1440, an H10 vaccine candidate
|
|
- Moderna initiates first-in-human dosing for mRNA-2416 , its OX40 ligand intratumoral immunotherapy
|
|
- Moderna initates first-in-human dosing for mRNA-1647, a vaccine candidate to protect against cytomegalovirus
|
|
- Moderna initiates first-in-human dosing for mRNA-1653, a multivalent vaccine to protect against human metapneumovirus and parainfluenza virus
|

|
- In collaboration with DARPA, Moderna introduces its first infectious disease therapeutic development candidate, mRNA-1944, encoding an antibody against Chikungunya virus
|
2016
|
|
- Lease signed to build 200,000 sq ft GMP mRNA clinical manufacturing facility in Norwood, MA, which opened in July 2018
|
---|

|
- BARDA funding award for up to $125M for Zika
|
|
- $474M equity financing (including $20M convertible note from Vertex)
|

|
- Vertex CFTR collaboration - $40M upfront, one target ($20M cash payment, $20M convertible note investment)
|
 |
- Merck partnership in personalized cancer vaccines - $200M upfront
|

|
- Charles River Laboratories (CRL) collaboration
|
|
- Moderna initiates first-in-human dosing for mRNA-1851, an H7N9 flu vaccine candidate
|
|
- Moderna introduces its first development candidate in its intratumoral immuno-oncology disease modality, mRNA-2416, encoding for OX40-Ligand intratumoral immunotherapy
|
 |
- Bill & Melinda Gates Foundation grant for HIV/AIDS - Up to $100M
|
 |
- Merck licenses additional vaccine candidate
|
 |
- AstraZeneca 50/50 collaboration in immuno-oncology - Two targets
|
 |
- Moderna introduces its first development candidate in its locatlized therapeutic modality, mRNA AZD-8601, encoding for VEGF-A
|

|
- Pharmaceutical Product Development, LLC (PPD) collaboration
|
2015
|
|
- Moderna introduces its first development candidate in its prophylactic disease modality, mRNA-1440, an H10N8 flu vaccine candidate.
|
---|
|
- Moderna initiates first-in-human dosing for mRNA 1440
|
 |
- Merck collaboration in infectious disease - $50M upfront, $50M equity, five targets
|
|
|
2014
|
 |
- Alexion strategic agreement in rare disease - $100M upfront, up to 10 targets
|
---|
2013
|
|
|
---|
|
- Expansion to new HQ and labs at 200 Technology Sq.
|

|
|
 |
- AstraZeneca collaboration in cardiometabolic disease and cancer - $240M upfront, up to 40 targets
|
2012
|
|
|
2011
|
|
|
2010
|
 |
|